Arecor and Medtronic have partnered to create a new type of insulin that would allow for the use of new insulin pump designs, which would sit under the skin, rather than on the surface. The collaboration aims to develop a novel, high-concentration, thermostable insulin for use by Medtronic in a next-generation pump. A new insulin of this kind could minimize the need for pump maintenance interventions and expand utility for physicians while saving costs.

Gary Dulak, senior director of new venture programs at Medtronic Diabetes explained that, “With an implantable insulin pump system, insulin delivery is targeted for direct absorption by the liver via the implantable pump. Arecor and Medtronic’s new insulin remains at an early stage in development and would still require clinical trials.

To find out more, CLICK HERE.